$PRSC (Providence Service Corp.)

$PRSC {{ '2016-03-11T05:21:43+0000' | timeago}} • Announcement

Health risk assessment company $PRSC reported 4Q15 net income available to stockholders of $63.7MM or $4.07 per diluted share, up 803.4% versus $7.1MM or $0.45 per diluted share in 4Q14, helped by income from discontinued operations, net of tax, of $101.5MM. Consolidated revenue rose 15.4% to $424.9MM versus $368.3MM in 2014.

$AMGN {{ '2017-07-26T19:57:57+0000' | timeago}} • Webcast

$AMGN has $39Bil cash on balance sheet, with no intention to consummate M&A transactions or repaying debt right now. The vast majority of cash is sitting offshore and the company is not considering to repatriate it under the current US tax system. The company said it will take a look at deploying the cash when some progress is made on tax reform.

$AMGN {{ '2017-07-26T19:34:18+0000' | timeago}} • Webcast

In 2Q17, $AMGN had a strong volume-driven growth from Prolia and other recently launched drugs including KYPROLIS and Repatha. Prolia sales increased 15% with an 18% volume growth YoY, with share gains in both the US and international markets.

$BIIB {{ '2017-07-26T13:59:55+0000' | timeago}} • Webcast

In multiple sclerosis, $BIIB's 2Q17 global TECFIDERA revenue growth was driven by volume growth, while patient growth in TECFIDERA was driven by its newly launched markets such as Italy, Poland & Japan. For FY17 ex-US, $BIIB expects SPINRAZA revenues to be modest, mainly from Germany and Japan. However, patient intake in the US is expected to grow.

$BIIB {{ '2017-07-26T13:46:38+0000' | timeago}} • Webcast

$BIIB's priority for capital deployment going forward is to invest in building its pipeline across its core growth areas like Alzheimer's, Parkinson's and neuromuscular disease and emerging areas like pain, ophthalmology and neuropsychiatry. $BIIB expects to have about $400MM available by 2019 for R&D and commercial value creation opportunities.

$AMGN {{ '2017-07-25T22:44:31+0000' | timeago}} • Announcement

$AMGN increased its 2017 earnings guidance to between $10.79 per share and $11.37 per share on GAAP basis, and between $12.15 per share and $12.65 per share on adjusted basis. Sales guidance was revised to a range of $22.5-23Bil.

$AMGN {{ '2017-07-25T22:43:15+0000' | timeago}} • Announcement

$AMGN reported a 15% YoY earnings growth in 2Q17 to $2.2Bil, or $2.91 per share, driven by a 4.9 percentage points increase in operating margin. Adjusted for one-time items, the company reported per-share earnings of $3.27. Revenue rose 2% to $5.8Bil.

$ESRX {{ '2017-07-25T21:31:49+0000' | timeago}} • Infographic

$ESRX Express Scripts Earnings AlphaGraphic: Q2 2017 Highlights

$AMGN {{ '2017-07-25T20:50:47+0000' | timeago}} • Infographic

$AMGN Amgen Earnings AlphaGraphic: Q2 2017 highlights

$ESRX {{ '2017-07-25T20:44:55+0000' | timeago}} • Announcement

$ESRX's enterprise value initiative is currently estimated to cost approx. $600-650MM and to deliver cumulative savings of nearly $1.2Bil by 2021. This initiative is expected to help the company achieve its targeted core PBM compounded annual EBITDA growth rate from 2017-2020 of 2-4%.

$ESRX {{ '2017-07-25T20:44:37+0000' | timeago}} • Announcement

$ESRX is updating its expected 2018 retention rate for the 2017 selling season to be 94-96%, excluding the impact of the remaining Coventry business rolling off in 2017. The company believes its contract with Anthem is unlikely to be extended even though Anthem has not yet issued a formal written notice regarding the contract renewal.

$ESRX {{ '2017-07-25T20:38:07+0000' | timeago}} • Announcement

$ESRX increased its guidance for 2017 adjusted diluted EPS to a range of $6.95-7.05, representing growth of 10% over 2016 adjusted diluted EPS results at the mid-point of the range. The company expects total adjusted claims for 3Q17 to be 340-350MM. Adjusted diluted EPS in 3Q17 is estimated to be $1.88-1.92, representing growth of 8-10% over 3Q16.

$ESRX {{ '2017-07-25T20:33:37+0000' | timeago}} • Announcement

$ESRX reported an 11% increase in 2Q17 earnings. Net income was $801.8MM compared to $720.7MM in 2Q16. Diluted EPS increased 21% to $1.37 from last year. Adjusted net income grew 1% to $1Bil and adjusted diluted EPS grew 10% to $1.73 in 2Q17. Revenues of $25.3Bil were relatively flat compared to the prior-year period.

$MMM {{ '2017-07-25T17:59:58+0000' | timeago}} • Webcast

$MMM said it had reduced prices of a number of products in 2Q17 to accelerate growth in areas where price seemed to be a barrier. The St Paul, Minnesota-based company added that it is currently at the peak of price declines and expects an upstick in pricing in 2H17.

$MMM {{ '2017-07-25T17:38:50+0000' | timeago}} • Webcast

$MMM, which makes Post-It notes, said it saw organic growth in three of its four Consumer segment businesses in 2Q17, namely Home Improvement, Home Supplies and Consumer Healthcare. Meanwhile, its Stationery and Office Supplies business was again impacted by inventory reductions in the US office retail and wholesale channels.

$MMM {{ '2017-07-25T17:23:43+0000' | timeago}} • Webcast

$MMM said it expects 20-25 cents per share impact from incremental strategic investments in 2H17, which is expected to drive greater productivity from its manufacturing and supply chain base.

$ABT {{ '2017-07-25T15:58:08+0000' | timeago}} • Announcement

$ABT has announced that the first patient has been enrolled in a clinical study evaluating the short-term use of common blood thinning medicines, called dual antiplatelet therapy (DAPT), after receiving a Xience everolimus-eluting coronary stent to unblock coronary arteries. Approx 2,000 patients at 100 sites in the US and Asia will be studied.

$LLY {{ '2017-07-25T15:33:57+0000' | timeago}} • Announcement

$LLY and its development and marketing partner $INCY announced that resubmission of rheumatoid arthritis drug baricitinib will be delayed beyond 2017 and at least it will take 18 months. FDA has demanded for a new trial. ELi Lilly added that baricitinib tablets have been approved since Feb 2017 in EU and the drug was approved recently in Japan.

$BIIB {{ '2017-07-25T15:15:33+0000' | timeago}} • Announcement

$BIIB named Alisha Alaimo as SVP of US Therapeutic Operations. In this position, Alaimo will lead $BIIB's sales and marketing, market access, patient services and commercial operations and strategy. Alaimo will join the company from $NVS, where she was VP and Head of its Cardiovascular Business Unit.

$BIIB {{ '2017-07-25T15:07:04+0000' | timeago}} • Announcement

On a segment basis, $BIIB's revenue for TECFIDERA, PLEGRIDY and FAMPYRA increased YoY in 2Q17, while total Total Interferon and AVONEX reported decline in revenues. In other products, Biosimilars revenue surged significantly to $91MM in the quarter from $15MM a year ago.

$BIIB {{ '2017-07-25T14:59:43+0000' | timeago}} • Announcement

Drugmaker $BIIB increased its revenue outlook for FY17 to $11.5-11.8Bil, due to faster than expected adoption of SPINRAZA in the US. GAAP diluted EPS guidance was narrowed to $17.05-17.65 from the earlier guidance of $18-18.80. Adjusted EPS guidance, however, was raised to $20.80-21.40 from the prior guidance of $20.45-21.25.

Recent Transcripts

CHE (Chemed Corp.)
Wednesday, July 26 2017 - 2:00pm
ESRX (Express Scripts Holding Company)
Wednesday, July 26 2017 - 12:30pm
AMGN (Amgen Inc)
Tuesday, July 25 2017 - 9:00pm
MMM (3M Company)
Tuesday, July 25 2017 - 1:00pm
LLY (Eli Lilly and Company)
Tuesday, July 25 2017 - 1:00pm
BIIB (Biogen Inc.)
Tuesday, July 25 2017 - 12:00pm
PETS (PetMed Express, Inc.)
Monday, July 24 2017 - 12:30pm
ABT (Abbott Laboratories)
Thursday, July 20 2017 - 1:00pm
USPH (US Physical Therapy Inc.)
Thursday, June 29 2017 - 2:30pm
KANG (iKang Healthcare Group, Inc.)
Friday, June 23 2017 - 12:00pm
MDT (Medtronic plc)
Thursday, May 25 2017 - 12:00pm
PMC (PharMerica Corporation)
Wednesday, May 10 2017 - 2:00pm
PRSC (Providence Service Corp.)
Wednesday, May 10 2017 - 12:00pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
PETS (PetMed Express, Inc.)
Monday, May 8 2017 - 12:30pm
MD (MEDNAX, Inc.)
Thursday, May 4 2017 - 2:00pm
MMS (MAXIMUS, Inc.)
Thursday, May 4 2017 - 1:00pm
BIOS (BioScrip, Inc.)
Thursday, May 4 2017 - 1:00pm
KND (Kindred Healthcare Inc.)
Thursday, May 4 2017 - 1:00pm
AMED (Amedisys Inc.)
Wednesday, May 3 2017 - 3:00pm

AlphaGraphics you may like